Forewords - JPMA · Forewords This data book organizes the statistics on pharmaceutical industries...
Transcript of Forewords - JPMA · Forewords This data book organizes the statistics on pharmaceutical industries...
Forewords
This data book organizes the statistics on pharmaceutical industries both in Japan and around the world. Those contain such figures as yearly transition of a variety of data such as demographic changes, national healthcare expenditure, and social security payments. Japan Pharmaceutical Manufacturers Association (JPMA) has also summarized pharmaceutical industries’ overall pictures including the outcome of our research to the member companies, delivering the data collected from a variety of different angles: environment of pharmaceutical industries or comparison with other industries, current situations of production of medicinal drugs, factors of expansion to non-Japanese countries, the latest situation of research and development, or trends in approval for new products. With the exception of some statistical data from government or other public agency sources, the latest data in this issue are for FY2014.
We would be grateful if this data book is utilized as a tool for promotion of understanding about pharmaceutical industries, making medical care policies, or planning strategies for pharmaceutical industries.
Since the 2015 issue, it has become possible to browse the DATA BOOK on the JPMA website. This DATA BOOK will therefore be the last to be published in printed form.
Issuance of the new edition of the Data Book owes so much to cooperation offered by a wide variety of relevant organizations: a variety of ministries including Ministry of Health, Labour and Welfare at the top, non-Japanese pharmaceutical manufacturers’ associations, research agencies, or member companies of JPMA. We here would like to appreciate all their effort and cooperation.
March 2016
Japan Pharmaceutical Manufacturers Association
前付け_eng.indd 1 16/03/18 20:51
User’s Guide
Please note the following when using the Data Book.
The survey results featured in the Report of the Pharmaceutical Industry
Survey are cited on pages 3 through 9. The surveys up to FY2005 targeted all the
companies whose head offices (1) manufacture and sell pharmaceuticals, (2)
manufacture drugs, and (3) import and sell drugs, as of the end of each business
year (March 31), based on a license for the Manufacture and Sale of Drugs, the
Manufacture of Drugs, and the Import and Sale of Drugs, under the Pharmaceutical
Affairs Law.
Among the companies, having obtained a pharmaceutical manufacturing and
marketing license under the Pharmaceutical Affairs Law as of the end of each
business year (March 31), the surveys since FY2006 targeted the member
companies under the fourteen industrial bodies affiliated with the Federation of
Pharmaceutical Manufacturers’ Associations of Japan.
Moreover, various numerical values for FY2004, including drug sales,
decreased by 15 to 20% from other years. This, however, was the result of a
considerable number of corporations, including large-scale entities, not being
incorporated as the compilation targets, causing the figures to deviate considerably
from the actual status. Therefore, these figures were not reproduced or included.
前付け_eng.indd 2 16/03/18 20:51
Abbreviated Names of Member Companies
Abbreviated Name Official Name
AbbVie AbbVieG.K.AjinomotoPharma. AJINOMOTOPHARMACEUTICALSCO.,LTD.Alcon AlconJapanLTD.AsahiKaseiPharma ASAHIKASEIPHARMACORPORATIONASKA ASKAPHARMACEUTICALCO.,LTD.Astellas ASTELLASPHARMAINC.AstraZeneca AstraZenecaK.K.AYUMI AYUMIPharmaceuticalCorp.Baxalta BaxaltaJapanLtd.Bayer BAYERYAKUHIN,LTD.BoehringerIngelheim NIPPONBOEHRINGERINGELHEIMCO.,LTD.Bristol-Myers BRISTOL-MYERSK.K.Celgene CelgeneK.K.Chugai CHUGAIPHARMACEUTICALCO.,LTD.DaiichiSankyo DAIICHISANKYOCO.,LTD.DainipponSumitomo DAINIPPONSUMITOMOPHARMACO.,LTD.Eisai EISAICO.,LTD.EliLilly ELILILLYJAPANK.K.Fujimoto FUJIMOTOPHARMACEUTICALCORP.Fuso FUSOPHARMACEUTICALINDUSTRIES,LTD.Genzyme GenzymeJapanK.K.GlaxoSmithKline GlaxoSmithKlineK.K.Hisamitsu HISAMITSUPHARMACEUTICALCO.,INC.Janssen JANSSENPHARMACEUTICALK.K.JapanTobacco JAPANTOBACCOINC.Kaken KAKENPHARMACEUTICALCO.,LTD.Kissei KISSEIPHARMACEUTICALCO.,LTD.Kowa KOWACompany,Ltd.KraciePharma KRACIEPHARMA,LTD.KyorinPharma. KYORINPHARMACEUTICALCO.,LTD.Kyoto KYOTOPHARMACEUTICALINDUSTRIES,LTD.KyowaHakkoKirin KYOWAHAKKOKIRINCO.,LTD.Maruho MARUHOCO.,LTD.Maruishi MARUISHIPHARMACEUTICALCO.,LTD.MeijiSeikaPharma MeijiSeikaPharmaCO.,LTD.MerckSerono MerckSeronoCO.,LTD.Minophagen MINOPHAGENPHARMACEUTICALCO.,LTD.
2_会社略名_eng.indd 1 16/03/18 20:51
Abbreviated Name Official Name
MitsubishiTanabe MITSUBISHITANABEPHARMACORPORATIONMochida MOCHIDAPHARMACEUTICALCO.,LTD.MSD MSDK.K.Mylan MylanEPDG.K.NihonPharma. NIHONPHARMACEUTICALCO.,LTD.NipponChemiphar NIPPONCHEMIPHARCO.,LTD.NipponKayaku NIPPONKAYAKUCO.,LTD.NipponShinyaku NIPPONSHINYAKUCo.,Ltd.NipponZoki NIPPONZOKIPHARMACEUTICALCO.,LTD.Novartis NOVARTISPHARMAK.K.NovoNordisk NOVONORDISKPHARMALTD.Ono ONOPHARMACEUTICALCO.,LTD.Otsuka OTSUKAPHARMACEUTICALCo.,Ltd.Pfizer PFIZERJAPANINC.POLAPHARMA POLAPHARMAINC.Sanofi SanofiK.K.Santen SANTENPHARMACEUTICALCO.,LTD.SanwaKagaku SANWAKAGAKUKENKYUSHOCO.,LTD.Seikagaku SEIKAGAKUCORPORATIONSenju SENJUPHARMACEUTICALCO.,LTD.Shionogi SHIONOGI&CO.,LTD.Taiho TAIHOPHARMACEUTICALCO.,LTD.Taisho TAISHOPHARMACEUTICALCO.,LTD.Takeda TAKEDAPHARMACEUTICALCOMPANYLIMITEDTeijinPharma TEIJINPHARMALIMITEDTeikokuSeiyaku TEIKOKUSEIYAKUCO.,LTD.Terumo TERUMOCORPORATIONToaEiyo TOAEIYOLTD.Toray TorayIndustries,Inc.Torii TORIIPHARMACEUTICALCO.,LTD.ToyamaChemical TOYAMACHEMICALCO.,LTD.Tsumura TSUMURA&CO.UCB UCBJAPANCO.,LTD.Wakamoto WAKAMOTOPHARMACEUTICALCO.,LTD.Yakult YAKULTHONSHACO.,LTD.Zeria ZERIAPHARMACEUTICALCO.,LTD.
2_会社略名_eng.indd 2 16/03/18 20:51
CONTENTS
Domestic Statistics ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 1 〜 55
International Statistics ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥57 〜 76
Statistics on Health ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥77 〜 97
Ⅰ.PHARMACEUTICAL INDUSTRY OUTLOOK Number of Pharmaceutical Manufacturers
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 3
Major Countries ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥59
Employment in the Pharmaceutical Industry
Japan, by Function ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 4
Europe, by Country ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥60
Number of Pharmaceutical Manufacturers by Number of Employees
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 5
Pharmaceutical Market
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 6, 14
Major Countries and Regions ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥61
Sales of Pharmaceutical Manufacturers by Capital Scale
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 7
Concentration on Pharmaceutical Sales to Leading Companies
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 8
Worldwide ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥62
Comparison of Pharmaceutical Sales between Domestic and Foreign Companies ‥‥‥ 9
Financial Results of JPMA Member Companies
All Member Companies ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥10 〜 13
Ethical Drug Sales
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥15
Financial Results of Leading Pharmaceutical Manufacturers
Japan, Financial Results ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥16 Worldwide, Operating Results ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥63
Worldwide, Financial Results ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥64
Value-Added Ratio of Industrial Sectors
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥17
目次_eng.indd 1 16/03/18 20:52
Profitability of Research based Industries
Japan, by Industry ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥18
Japan, Leading Companies ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥19
U.S.A. and Europe, Leading Companies ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥65
International Trade of Pharmaceutical Products
Japan, by Year ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥20
Japan, Partner Country ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥21
Major Countries ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥66
Exports, Partner Country ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥67
Imports, Partner Country ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥68
Overseas Business of Japanese Pharmaceutical Companies ‥‥‥‥‥‥‥‥‥‥‥22 〜 23
Expansion into Overseas Markets by JPMA Member Companies ‥‥‥‥‥‥‥‥‥24 〜 26
Overseas Sales of Leading Pharmaceutical Manufacturers
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥16
Worldwide(excluding Japanese Manufacturers) ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥69
Miscelleneous Indexes ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥70
Ⅱ.PHARMACEUTICAL PRODUCTION Pharmaceutical Production
Japan, by year ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥29
Japan, by Therapeutic Category ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥30
Trends in Ethical Drug Production by Composition Ratio of Main Therapeutic Category
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥31
Pharmaceutical Production by Dosage Forms
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥32
Ethical Drug Production and National Health Care Expenditures
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥33
Ⅲ.PHARMACEUTICAL RESEARCH AND DEVELOPMENT R&D Expenditures of the Pharmaceutical Industry
Japan, by Year ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥37
R&D Expenditures of Leading Pharmaceutical Manufacturers
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥38
Worldwide(excluding Japanese Manufacturers) ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥73
R&D Expenditures by Developmental Stage
U.S.A. ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥74
目次_eng.indd 2 16/03/18 20:52
Trends of R&D Expenditures and Profits as Sales Ratio
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥39
U.S.A. ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥75
R&D Expenditures as a Percentage of Sales by Industry
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥40
R&D Expenditures by Industry and Type
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥41
Number of Pharmaceutical Approvals Granted in Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥42
Number of Pharmaceuticals Included in the NHI Price List in Japan ‥‥‥‥‥‥‥‥‥‥‥43
Number of New Molecular Entities Approved
Japan, by year ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥44
Japan, Leading Companies, (Accumulation from 2000) ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥45
Success Rate of Developing New Drugs
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥46
Median Development Times for New Molecular Entities
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥47
Median Approval Times for New Drugs
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥48
Review Process for Approval
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥49
Trends in Notification of Clinical Trials
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥50
Number of Drug Patents
Japan, by Year ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥51
Japan, Domestic Applicant ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥52
Japan, Foreign Applicant ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥53
Published PCT Applications by Pharmaceutical Company ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥76
Number of Bio-technology Patents ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥54
Technology Exports and Imports in the Pharmaceutical Industry
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥55
STATISTICS ON HEALTH CARE Life Expectancy
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥79
Worldwide ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥80
Trends of Vital Statistics
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥81
Foreign Countries ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥82
目次_eng.indd 3 16/03/18 20:52
Mortality Rate by Major Causes
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥83
Major Countries ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥84
National Health Care Expenditures
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥85
Major Countries ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥86
National Health Care Expenditures - % GDP
Major Countries ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥87
National Health Care Expenditures and Share by Source of Revenues
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥88
U.S.A. ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥89
Proportion of National Treasury Expenses in National Health Care Expenditures
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥90
U.S.A. ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥91
Social Benefit ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥92
Number of Medical Care Facilities
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥93
Number of Beds in Medical Care Facilities
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥94
Number of Medical Care Personnel
Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥95
M&A
in Japan ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥96
in the World ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥97
(Appendix)
List of JPMA Member Companies ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 100 〜 101
Exchange Rates ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 104
目次_eng.indd 4 16/03/18 20:52
— DOMESTIC STATISTICS —
Ⅰ . Pharmaceutical Industry Outlook
DO
ME
STIC
ST
ATIS
TIC
S
Ⅰ. P
harm
aceu
tica
l Ind
ustr
y O
utlo
ok
扉_eng.indd 1 16/03/18 20:52
− 3 −
Number of Pharmaceutical ManufacturersJapan
FiscalYear Total Ethical Drug
ManufacturersOTC Drug
ManufacturersOther
Manufacturers
Manufacturerswith NHI
Price listedDrugs
JPMAMembers
* Refer to the User's Guide.
Source : Ministry of Health, Labour and Welfare, Statistics on Pharmaceutical and Medical Device Industry http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001034412 Manufacturers with NHI Price listed Drugs: Jiho, NHI Drug Price Directory by Therapeutic Category August issues of each year
Note : The figures within parentheses show the number of generic makers.
1_01_医薬品産業の現況_eng.indd 3 16/03/18 20:53
− 4 −
Employment in the Pharmaceutical IndustryJapan, by Function Unit : %, no. of persons
* Refer to the User's Guide.
Note : 1 The number of employees counted in this figure belongs to the pharmaceutical divisions. 2 Instructors are not included in ‘Medical Representative’. 3 The figures in the parenthesis show the number of surveyed companies. 4 The sum of the categories does not equal to JPMA total sum shown due to incomplete responses. The figures in the parenthesis in this row show the number of companies responded.
Source : Ministry of Health, Labour and Welfare, Statistics on Pharmaceutical and Medical Device Industry , http://www.mhlw.go.jp/toukei/list/87-1.html
MedicalRepresentative
Research &Development Marketing
ResearchersFiscalYear Total Administration Production &
Quality Control
1_01_医薬品産業の現況_eng.indd 4 16/03/18 20:53
− 5 −
Number of Pharmaceutical Manufacturers by Number of EmployeesJapan % in parentheses
Fiscal Year
* Refer to the User s Guide.
Source : Ministry of Health, Labour and Welfare, Statistics on Pharmaceutical and Medical Device Industry , http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001034412
101300
3011,000
Over3,001 Total1,001
3,00010 employees
or less1150
51100
1_01_医薬品産業の現況_eng.indd 5
16/03/18 20:53
− 6 −
Pharmaceutical MarketJapan Manufacturers Sales Unit : JPY bil.
Generic drugs
* Refer to the User's Guide.
Note : 1. ‘Ethical drugs’ includes in vitro diagnostics. 2. ‘Raw materials and Others’ includes bulk products and medical supplies such as hygiene products. The figures from 2006 include products sold by distributors. 3. The figures in parenthesis are the number of companies surveyed.
Source : Ministry of Health, Labour and Welfare, Statistics on Pharmaceutical and Medical Device Industry , http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001034412
Raw materialsand Others
FiscalYear Total Ethical drugs OTC drugs
1_01_医薬品産業の現況_eng.indd 6 16/03/18 20:53
− 7 −
Sales of Pharmaceutical Manufacturers by Capital ScaleJapan FY2013* : 345 Companies Unit : JPY mil.
Less than10 mil.
10 50 mil.
50 100 mil.
100 300 mil.
300 mil.1 bil.
1 5 bil.
Over5 bil. Total
Generic
Raw materials and Others
Generic
Raw materials and Others Total
Generic
Raw materials and Others
* Refer to the User's Guide.
Note : 1. ‘Ethical drug’ includes in vitro diagnostics. 2. ‘Raw materials and Others’ includes bulk products, medical supplies e.g. hygiene products and in-house products sold by distributors.
Source : Ministry of Health, Labour and Welfare, Statistics on Pharmaceutical and Medical Device Industry , http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001034412
DiversifiedCompanies
Ethical Drug
OTC
Total
Ethical Drug
OTC
Total
ProductCategory
Capital Scale
SpecializedPharmaceutical
Companies
Ethical Drug
OTC
Total
1_01_医薬品産業の現況_eng.indd 7
16/03/18 20:53
−8
−
Concentration on Pharmaceutical Sales to Leading CompaniesJapan Unit : %
FiscalYear
5 LeadingCompanies
10 LeadingCompanies
30 LeadingCompanies
50 LeadingCompanies
100 LeadingCompanies
TotalCompanies
* Refer to the User s Guide.
Source : Ministry of Health, Labour and Welfare, Statistics on Pharmaceutical and Medical Device Industry , http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001034412
1_01_医薬品産業の現況_eng.indd 8
16/03/18 20:53
− 9 −
Comparison of Pharmaceutical Sales between Domestic and Foreign Companies
Total Sales JPY mil.
Ratio %
Counted Companies
Total Sales JPY mil.
Ratio %
Counted Companies
Total Sales JPY mil.
Ratio %
Counted Companies
* Refer to the User s Guide.
Source : Ministry of Health, Labour and Welfare, Statistics on Pharmaceutical and Medical Device Industry , http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001034412
Fiscal Year
Domestic
Foreign
Total
%
Fiscal Year
Ratio of Foreign Company
* * * *
1_01_医薬品産業の現況_eng.indd 9 16/03/18 20:53
−10
−
Financial Results of JPMA Member Companies
Company
Fiscal Year
AbbVie
Ajinomoto Pharma.
Asahi Kasei Pharma*
ASKA
Astellas
AstraZeneca*
Bayer*
Boehringer Ingelheim
Chugai
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly*
Fuso*
Genzyme Japan*
Unit : JPY mil.
Total Sales Pharmaceutical Sales Operating Income Ordinary Income Net Income No.of Employees
1_01_医薬品産業の現況_eng.indd 10
16/03/18 20:53
− 11 −
Company
Fiscal Year
Hisamitsu
Japan Tobacco
Kaken
Kissei
Kowa
Kracie Pharma
Kyorin Pharma.*
Kyowa Hakko Kirin
Maruho*
Maruishi*
Meiji Seika Pharma
Minophagen
Mitsubishi Tanabe
Mochida
MSD*
Nippon Chemiphar
Unit : JPY mil.
Total Sales Pharmaceutical Sales Operating Income Ordinary Income Net Income No.of Employees
1_01_医薬品産業の現況_eng.indd 11
16/03/18 20:53
−12
−
Company
Fiscal Year
Nippon Kayaku
Nippon Shinyaku
Nippon Zoki*
Novartis*
Ono
Otsuka*
Pfizer*
Sanofi*
Santen
Sanwa Kagaku*
Seikagaku
Senju*
Shionogi
Taiho*
Taisho
Unit : JPY mil.
Total Sales Pharmaceutical Sales Operating Income Ordinary Income Net Income No.of Employees
1_01_医薬品産業の現況_eng.indd 12
16/03/18 20:53
− 13 −
Company
Fiscal Year
Takeda
Teijin Pharma
Teikoku Seiyaku*
Toa Eiyo*
Toray
Torii*
Toyama Chemical*
UCB*
Wakamoto*
Yakult
Zeria
*Non-consolidated Financial Statements
Note : 1. Only includes JPMA members who responded to the survey. 2. ‘ ’ represents invalid answers or not-public.
3. Total Sales of Japan Tobacco shows Sales Revenues in this table. 4. FY2014 data for AbbVie Inc. is that for Abbott Laboratories.
Source : JPMA Survey questionnaire survey to member companies , Financial statements.
Unit : JPY mil.
Total Sales Pharmaceutical Sales Operating Income Ordinary Income Net Income No.of Employees
1_01_医薬品産業の現況_eng.indd 13
16/03/18 20:53
−14
−
Ethical Drug Market
Japan Unit : JPY mil.
NHI price basis Change % NHI price
basis Change % NHI price basis Change % NHI price
basis Change %
2016 IMS Health
Source : IMS Japan, Calculated based on Japan Pharmaceutical Market Sales 2005-2015(Reprinted with permission)
Year
Hospitals General Practitioners Others Total
1_01_医薬品産業の現況_eng.indd 14
16/03/18 20:53
− 15 −
Ethical Drug Sales
Japan 2014 Jan.-Dec.Promotion Company Level Unit : JPY mil. Distributor Level Unit : JPY mil.
Company SalesNHI price basis Company Sales
NHI price basis Pfizer Takeda Takeda Astellas Daiichi Sankyo Daiichi SankyoChugai Chugai MSD Pfizer Novartis Pharma Mitsubishi Tanabe Mitsubishi Tanabe MSD AstraZeneca Novartis Pharma Sanofi Otsuka GlaxoSmithKline GlaxoSmithKline Otsuka Eisai Astellas Sanofi Eisai Eli Lilly Japan Nippon Boehringer Ingelheim Kyowa Hakko Kirin Bayer Bayer Eli Lilly Japan Shionogi Kyowa Hakko Kirin Dainippon Sumitomo Shionogi AstraZeneca Dainippon Sumitomo Janssen Ono Ono
2016 IMS Health
Source : IMS Japan, Calculated based on Japan Pharmaceutical Market Sales 2015 (Reprinted with permission)
1_01_医薬品産業の現況_eng.indd 15
16/03/18 20:53
−16
−
Financial Results of the Leading Pharmaceutical Manufacturers
Japan FY2014 Consolidated Accounts
JPY mil. % JPY mil. % JPY mil. % Takeda Astellas Otsuka Holdings Daiichi Sankyo Eisai Kowa Mitsubishi Tanabe Dainippon Sumitomo Kyowa Hakko Kirin Taisho Shionogi Santen Hisamitsu Ono Kyorin Tsumura Kaken Mochida Nippon ShinyakuKissei
Note : Takeda, Astellas, Eisai, Daiichi Sankyo, Santen, and Ono have adopted IFRS (International Financial Reporting Standards) in their financial statements. In the case of a consolidated financial statements using IFRS only, the data have been handled in the following way. Ordinary income figures (in yen and %) are not stated, and income in the current term is taken to be net income.
Source : SPEEDA (UZABASE, Inc.), Financial statements
Return onAsset
%
Return onEquity
%
Overseas SalesCompany Sales
JPY mil.Ordinary Income Net Income Total
AssetsJPY mil.
EquityRatio
%
1_01_医薬品産業の現況_eng.indd 16
16/03/18 20:53
− 17 −
Value-Added Ratio of Industrial SectorsJapan
No.ofFirmsInves-tigated
Value-AddedRatio
%
No.ofFirmsInves-tigated
Value-AddedRatio
%
No.ofFirmsInves-tigated
Value-AddedRatio
%
No.ofFirmsInves-tigated
Value-AddedRatio
%
No.ofFirmsInves-tigated
Value-AddedRatio
%
No.ofFirmsInves-tigated
Value-AddedRatio
%
Manufacturing Industries
Foods
Textiles
Paper & Pulp
Printing
Chemicals
Chemicals-Major
Organic Chemicals
Inorganic Chemicals
Oil, Fats & Cosmetics
Paints
Pharmaceuticals
Petroleum
Rubber Products
Stone, Clay & Glass Pds.
Iron & Steel
Nonferrous Metals
Fabricated Metal Products
Machinery
Electric Equipment
Computers & Electric Eq.
Industrial Electric Eq.
Communications Equipment
Electric Measuring Instr.
Electric Eq. & Comp.
Household Electric Appl.
Transportation Equipment
Automobiles
Auto Parts & Accessories
Precision Instruments
Misc. Manufacturing
Source : Development Bank of Japan, Handbook of Industrial Financial Data
Formulation Value added ratio % Value added Adjusted sales 100
Industry
1_01_医薬品産業の現況_eng.indd 17 16/03/18 20:53
−18
−
Profitability of Research-based Industries
Japan Unit : %
Net Income Loss after Taxes Business Income to Total Assets Return on Equity Net Income Loss after Taxes Business Income to Total Assets Return on Equity Net Income Loss after Taxes Business Income to Total Assets Return on Equity Net Income Loss after Taxes Business Income to Total Assets Return on Equity Net Income Loss after Taxes Business Income to Total Assets Return on Equity Net Income Loss after Taxes Business Income to Total Assets Return on Equity Net Income Loss after Taxes Business Income to Total Assets Return on Equity
Source : Development Bank of Japan, Handbook of Industrial Financial Data The pharmaceutical companies surveyed include Kyowa Hakko Kirin, Kaken, Hisamitsu, Mitsubishi Tanabe, Eiken Chemical, Eisai, Ono, Santen, Shionogi, Dainippon Sumitomo, Takeda, Chugai, ASKA, Nippon Chemiphar, Nippon Shinyaku, Morishita Jintan, Mochida, Astellas, Rohto, Nichi-Iko, Zeria, Seikagaku, Tsumura, Kissei, Towa, Sawai, SNBL(Shin Nippon Biochemical Laboratories), Daiichi Sankyo, Taisho Pharmaceutical Holdings
Formulation Total asset employed : Current assets Non-current assets Deferred Assets Note discounted Operating income loss : Sales income loss Accounts receivable and dividends Business income to total assets % Operating income loss Total assets 100 Return on equity % Net income Equity 100
Optical Instruments 5 companies Manufacturing Industries 972 companies
Pharmaceuticals29 companies
Computers & Electric Eq. 5 companies Electronic Eq. & Comp. 61 companies Household Electric Appl. 19 companies
Automobiles 10 companies
1_01_医薬品産業の現況_eng.indd 18
16/03/18 20:53
− 19 −
Profitability of Research-based Companies Specific companies by sector
Japan FY2014
SalesJPY mil.
OrdinaryIncomeJPY mil.
Return onAsset
%
Return onEquity
%
Net IncomeMargin
%
Takeda IFRS
Astellas IFRS
Daiichi Sankyo IFRS
Panasonic* SEC
Hitachi* IFRS
Toshiba* SEC
Toyota* SEC
Nissan Japan
Honda* IFRS
NEC Japan
Fujitsu IFRS
Sony* SEC
Canon* SEC
Ricoh* IFRS
Note: IFRS: International Financial Reporting Standards, SEC: Generally Accepted Accounting Principles (U.S.)
Source : SPEEDA (UZABASE, Inc.), Financial statements
Precision Machinery
Pharmaceuticals
Electric Machinery & Equipment
Automobiles
Communication & Electronic Machinery & Equipment
1_01_医薬品産業の現況_eng.indd 19
16/03/18 20:53
−20
−
International Trade of Pharmaceutical ProductsJapan
Value A Change % Value B Change % Value B/A times
Source : Ministry of Finance, Trade Statistics of Japan , http://www.customs.go.jp/toukei/suii/html/time.htm
Unit : JPY mil., %
YearExports Imports Trade Deficit
1_01_医薬品産業の現況_eng.indd 20
16/03/18 20:53
− 21 −
International Trade of Pharmaceutical Products by Partner Countries
JapanExports to : Unit : JPY mil., %
U.S.A. China Korea Switzerland Taiwan Germany France Belgium Netherlands Italy Hong Kong Thailand U.K. Indonesia India Singapore Spain Mexico Brazil Australia Philippine Canada Turkey Others Total
Imports from : Unit : JPY mil., %
U.S.A. Germany Switzerland France Singapore Italy Belgium U.K. China Spain Canada Korea Netherlands Australia Mexico Taiwan Brazil Others Total
Source : Ministry of Finance, Trade Statistics of Japan , http://www.customs.go.jp/toukei/suii/html/time.htm
CountryValue Share
CountryValue Share
1_01_医薬品産業の現況_eng.indd 21 16/03/18 20:53
− 22 −
Overseas Business of Japanese Pharmaceutical Companies
Overseas Subsidiaries Equity ownership of more than 50%
ManufactureProduction Plant
MarketingIncluding Import
Note : 1. Japanese overseas subsidiaries whose investment ratio is more than 50% independently. 2. Business relating to pharmaceutical bulk products, medical devices and equipments, nutrition-tonics and R&D activities are included.
Source : Yano Research Institute
Fiscal YearNo. of
PharmaceuticalCompanies
1_01_医薬品産業の現況_eng.indd 22 16/03/18 20:53
− 23 −
Overseas Business of Japanese Pharmaceutical Companies
Number of Japanese Companies by Country
No. ofCompanies
Percentageof total
No. ofCompanies
Percentageof total
No. ofCompanies
Percentageof total
No. ofCompanies
Percentageof total
No. ofCompanies
Percentageof total
No. ofCompanies
Percentageof total
U.S.A.
U.K.
Germany
France
China
Taiwan
Indonesia
Korea
Hong Kong
Singapore
Others
Total
Note : 1. Japanese overseas subsidiaries whose investment ratio is more than 50% independently. 2. Business relating to pharmaceutical bulk products, medical devices and equipments, nutrition-tonics and R&D activities are included.
Source : Yano Research Institute
1_01_医薬品産業の現況_eng.indd 23
16/03/18 20:53
− 24 −
Expansion into Overseas Markets by JPMA Member Companies*
1. Overseas Sales
Fiscal Year No. ofCompanies
Note : No. of Companies represents number of valid answers only.
2. Number of Employees - Overseas
No. ofEmployees
No. ofCompanies
No. ofEmployees
No. ofCompanies
No. ofEmployees
No. ofCompanies
No. ofEmployees
No. ofCompanies
Note : 1. No. of Companies represents the companies who have their own employees in that region. 2. The total number of employees being greater that the total of the numbers of employees in the three regions reflects the fact that some companies responded by giving only the total number of employees.
*Survey of companies with more than 50% domestic capital.Source : JPMA Survey
Fiscal YearNorth America Europe Asia and Others Total
Overseas Sales JPY mil.
1_01_医薬品産業の現況_eng.indd 24 16/03/18 20:53
− 25 −
3. Number of Overseas Bases
Note : No. of Companies represents number of valid answers only.
4-1. Number of Laboratories by Geographic Area
Denmark Spain
Brazil
From 2005, all countries are shown in the schedule. No. of companies of the total column shows the number of companies having the laboratories abroad.
Source : JPMA survey
No. ofCompanies
No. ofFacilities
No. ofCompanies
Fiscal YearLaboratory R&D Bases Factory
No. of Facilities
No. ofCompanies
No. of Facilities
No. ofCompanies
No. of Facilities
No. ofCompanies
CountryNo. of
FacilitiesNo. of
CompaniesNo. of
FacilitiesNo. of
CompaniesNo. of
FacilitiesNo. of
CompaniesNo. of
FacilitiesNo. of
CompaniesNo. of
Facilities
U.S.A. Canada U.K. Netherlands Switzerland
Germany France
Ireland Italy
Korea China
India Taiwan
Singapore
Indonesia Others
Note : In 2000, the survey required specification of 10 countries. The other countries are shown as ‘Others’.
Total
1_01_医薬品産業の現況_eng.indd 25 16/03/18 20:53
− 26 −
4-2. Number of R&D Bases by Geographic Area
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
U.S.A. Canada U.K. Germany Switzerland Netherlands Finland France Ireland Denmark China Singapore Korea Taiwan Brazil
Total
Note : No. of companies of the total column shows the number of companies having the R&D Bases abroad.
4-3. Number of Factories by Geographic Area
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
No. ofFacilities
No. ofCompanies
U.S.A. Canada Ireland Denmark Norway Finland Germany Spain Italy U.K. France Netherlands Belgium Austria Switzerland Poland Russia Estonia China Indonesia Taiwan Vietnam Korea Thailand India Philippines Malaysia Pakistan Mexico Brazil Colombia Argentina Venezuela Egypt Others
Total
Note : In 2000, the survey required specification of 10 countries. The other countries are shown as ‘Others’. From 2005, all countries are shown in the schedule. No. of companies of the total column shows the number of companies having the factories abroad.
Source : JPMA Survey
Country
Country
1_01_医薬品産業の現況_eng.indd 26 16/03/18 20:53
— DOMESTIC STATISTICS —
Ⅱ . Pharmaceutical Production
DO
ME
STIC
ST
ATIS
TIC
S
Ⅱ. P
harm
aceu
tica
l Pro
duct
ion
扉_eng.indd 2 16/03/18 20:52
− 29 −
Pharmaceutical Production
Japan
ValueJPY bil.
Import/Ethicals %
Note : 1. Imports means pharmaceutical products manufactured from imported active ingredients. 2. JPMA Total is based on fiscal year data.
Source : Ministry of Health, Labour and Welfare, Statistics of Production by Pharmaceutical Industry , http://www.mhlw.go.jp/topics/yakuji/2013/nenpo/1.html Economic and Social Research Institute, Cabinet Office, Statistics of GDP , http://www.esri.cao.go.jp/jp/sna/menu.html JPMA Survey
'14 JPMA Total
Year
Pharmaceutical Production
Percentageof GDPTotal
JPY bil.Change
%
Ethicals
ValueJPY bil.
Change%
% ofTotal
Imports
1_02_医薬品生産の現況_eng.indd 29
16/03/18 20:53
−30
−
Pharmaceutical Production by Therapeutic Category
Japan 2013 Unit : JPY mil., %
% of Total Total CNS Peripheral nervous system Sensory organ Cardiovascular system Respiratory system Gastrointestinals Hormones Genito-urinary system Dermatologicals Dental use Other agents affecting individual organs Vitamins Nutrients/Tonics Blood/Blood forming organs Artificial dialysis agents Other metabolic agents Agents activating cellular function Antitumor agents Radio pharmaceuticals Antiallergics Crude drugs Chinese herbal drugs Other natural drugs & Chinese medicine Antibiotics Chemotherapeutics Biological products Antiparasitics Dispensing drugs Diagnostics, In Vivo Hygiene products Diagnostics, In Vitro Other agents Alkaloidal narcotics Non-alkaloidal narcotics
Note : ‘Imports’ consists of pharmaceutical products manufactured from imported active ingredients.
Source : Ministry of Health, Labour and Welfare, Statistics of Production by Pharmaceutical Industry , http://www.mhlw.go.jp/topics/yakuji/2013/nenpo/xls/04.xls
Therapeutic Category TotalEthical Drug
OTC, etc.Sub-total Domestic
Products Imports
1_02_医薬品生産の現況_eng.indd 30
16/03/18 20:53
− 31 −
Trends in Ethical Drug Production by Composition Ratio of Main Therapeutic Category
Japan Unit : %
YearCardio-vascularagents
C.N.S.agents
Othermetabolic
agents
Blood/Bloodformingorgans
Gastro-intestinalagents
Bio-logicals
Anti-allergics
Dermato-logicalagents
Anti-biotics
In vitroDiagnostics
Note : 1. The numbers in parenthesis represent the production ranking of the main therapeutic category. 2. Chemotherapeutic agents ranks 10th in 1995 and during 2001 through 2004.
Source : Ministry of Health, Labour and Welfare, Statistics of Production by Pharmaceutical Industry , http://www.mhlw.go.jp/topics/yakuji/2013/nenpo/xls/04.xls
1_02_医薬品生産の現況_eng.indd 31
16/03/18 20:53
−32
−
Pharmaceutical Production by Dosage Forms Japan Unit : JPY mil., %
Value Share Value Share Value Share Value Share Value Share Value Share
Powders and granules etc.
Tablets
Pills*1
Capsules
Oral liquid preparations
Injections*2
Powders for injection*3
Solution for external application
Aerosols
Ointments and creams
Suppositories
Cataplasms etc*4
Others
Total
*1 Usually prepared by mixing drugs uniformly with diluents, binders and others and rolling into spherical form*2 Solutions, Suspensions or Emulsions*3 To be dissolved before use*4 Pasty Preparation or those spread on cloth or plastic film for external application
Source : Ministry of Health, Labour and Welfare, Statistics of Production by Pharmaceutical Industry , http://www.mhlw.go.jp/topics/yakuji/2013/nenpo/19.html
Dosage Form
1_02_医薬品生産の現況_eng.indd 32
16/03/18 20:53
− 33 −
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
22,000
24,000
26,000
28,000
30,000
32,000
34,000
36,000
38,000
40,000
200099989796 2001 2003 2004 2005 2006 2007 2008 2009 20102002 2012201196959085
Ethical Drug Production and National Health Care Expenditures
Ethical Drug Production('12)¥6,263.0 bil.
JPY bil.
Note : MHLW renewed the definition of manufactured products and imported products in 1996.
Source : Ministry of Health, Labour and Welfare, Estimates of National Medical Care Expenditure, http://www.mhlw.go.jp/toukei/list/37-21c.html Ministry of Health, Labour and Welfare, Statistics of Production by Pharmaceutical Industry, http://www.mhlw.go.jp/toukei/list/105-1c.html
National Health CareExpenditures('12)¥39,211.7 bil.
1_02_医薬品生産の現況_eng.indd 33 16/03/18 20:53
— DOMESTIC STATISTICS —
Ⅲ . Pharmaceutical Research and Development
DO
ME
STIC
ST
ATIS
TIC
S
Ⅲ. P
harm
aceu
tica
l Res
earc
h an
d D
evel
opm
ent
扉_eng.indd 3 16/03/18 20:52
− 37 −
R&D Expenditures of the Pharmaceutical Industry
Japan
Value %
Source : Ministry of Internal Affairs and Communications, Report on the Survey of Research and Development , http://www.stat.go.jp/data/kagaku/kekka/kekkagai/pdf/27ke_gai.pdf
Unit : JPY bil., %
Fiscal Year
R&DExpenditures
Change from the previous year Percentage of Sales
1_03_研究開発の現況_eng.indd 37 16/03/18 20:54
−38
−
R&D Expenditures of 20* Major Pharmaceutical ManufacturersJapan
Expendi-tures
Change%
R&D/Sales
%
Expendi-tures
Change%
R&D/Sales
%
Expendi-tures
Change%
R&D/Sales
%
Expendi-tures
Change%
R&D/Sales
%
Expendi-tures
Change%
R&D/Sales
% Takeda Astellas Otsuka Holdings Daiichi Sankyo Eisai Kowa Mitsubishi Tanabe Dainippon Sumitomo Kyowa Hakko Kirin Taisho Shionogi Santen Hisamitsu Ono Kyorin Tsumura Kaken Mochida Nippon ShinyakuKissei
* Top 20 companies in consolidated sales in FY2014 (excluding those companies with a pharmaceutical sales share of less than 30%)
Note : 1. R&D/Sales % is the ratio of research cost to total sales. 2. Merged companies pre-merger numbers are the combined numbers of company before merger. 3. The figure for Kyorin Holdings, Inc. in 2005 is R&D expenditures for Kyorin Pharmaceutical Co., Ltd. 4. Otsuka Holdings expenditures up to 2005 are Otsuka s figures. 5. Takeda, Astellas, Eisai, Daiichi Sankyo, Santen, and Ono adopted IFRS in their financial statements for FY2014.
Source : SPEEDA (UZABASE, Inc.), Financial statements
Unit for Expenditures, JPY mil.
Company
1_03_研究開発の現況_eng.indd 38
16/03/18 20:54
− 39 −
17.918.3 18.4 18.9
7.3
32.133.4
34.6 36.938.6
7.3 7.6
8.3 7.5 8.5
11.7 12.0 11.812.6
14.3
43.3
48.853.9
58.8
61.2 62.1
9.1 9.1
10.5
7.88.8
11.7
11.2
13.8 13.3
11.1
12.9 12.7
13.814.2 14.2
74.7
85.8
14.6
14.8
13.3
5.9
15.3
16.9 18.2
20.9
19.1
10.6
18.9
10.0
112.5
133.3
139.0
136.0
127.4126.2
119.0
125.0
Japan(10 companies)JPY bil.
(Fisical Year)
R&D Expenditures per Company(Average of 10 companies)
Net Profit Margin (%)
R&D Expenditures per Sales (%)
20111994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
to 2004 : Takeda, Sankyo, Yamanouchi, Daiichi, Taisho, Eisai, Shionogi, Fujisawa, Chugai, and Tanabe. 2005 : Takeda, Astellas, Eisai, Sankyo, Daiichi, Chugai, Mitsubishi, Dainippon Sumitomo, Shionogi, and Taisho. 2006 : Takeda, Astellas, Daiichi Sankyo, Eisai, Dainippon Sumitomo, Mitsubishi, Shionogi, Tanabe, Taisho, and Ono.
from 2007 : Takeda, Astellas, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Dainippon Sumitomo, Shionogi, Taisho(from 2013 Taisho Holdings), Ono and Otsuka Holdings(took Otsuka’s consolidated result for 2007). 2. Consolidated basis since 1999. 3. Chugai had an irregular 9 months financial result (Apr.-Dec.) in FY2003.
Note : 1. Companies surveyed :
Source : SPEEDA (UZABASE, Inc.), Financial statements
%40
35
30
25
20
15
10
5
0
140
135
130
125
120
115
110
105
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
0
Trends of R&D Expenditures and Profits as Sales Ratio
2012 2013 2014
1_03_研究開発の現況_eng.indd 39 16/03/18 20:54
−40
−
R&D Expenditures as a Percentage of Sales by Industry
Japan Unit : %Industry
All Industries* Agriculture, Forestry & Fisheries Mining, Quarrying & Gravel Extraction Construction Manufacturing Food Textiles Pulp, Paper& Paper Products Publishing, Printing & Allied Industries Pharmaceuticals Chemicals Industrial Chemicals Oils & Paints Other Chemicals Petroleum & Coal Products Plastic Products Rubber Products Ceramics, Stone & Clay Products Iron & Steel Non-ferrous Metals & Products Metal Products General Machinery Machinery & Tools for Production Machinery & Tools for Institutional Use Electric Component, Devices, Electric Circuit Electric Machinery Electronic Equipment & Electric Measurements Other Electric Machinery Information & Telecommunications Equipment Transportation Equipment Motor Vehicles & its Accessories Other Transport Equipment Precision Instruments Other Manufacturing Information & Communication Information Services
*Excluding special public corporations, independent administrative institutions IAIs , and finance and insurance industries.
Note : Japan Standard Industrial Classification was revised in FY2007.
Source : Ministry of Internal Affairs and Communications, Report on the Survey of Research and Development , http://www.stat.go.jp/data/kagaku/kekka/kekkagai/pdf/27ke_gai.pdf
1_03_研究開発の現況_eng.indd 40
16/03/18 20:54
− 41 −
R&D Expenditures by Industry and Type
Japan FY2014
Industry BasicResearch
AppliedResearch Development
All Industries
Agriculture, Forestry & Fisheries Mining, Quarrying & Gravel Extraction Construction Manufacturing Food Textiles Pulp, Paper & Paper Products Publishing, Printing & Allied Industries Pharmaceuticals JPMA Member Firms* Chemicals Petroleum & Coal Products Plastic Products Rubber Products Ceramics, Stone & Clay Products Iron & Steel Non-ferrous Metals & Products Metal Products Machinery & Tools for Production Machinery & Tools for Institutional Use Electric Component, Devices, Electric Circuit Electric Machinery Electronic Equipment & Electric Measurements Other Electric Machinery Information & Telecommunications Equipment Transportation Equipment Motor Vehicles & its Accessories Other Transport Equipment Other Manufacturing Information & Communication
*JPMA Survey (31 companies of JPMA members responded to the survey.) Source : Ministry of Internal Affairs and Communications, Report on the Survey of Research and Development , http://www.e-stat.go.jp/SG1/estat/GL08020103.do?_toGL08020103_&tclassID= 000001055409&cycleCode=0&requestSender=search
Unit : %
1_03_研究開発の現況_eng.indd 41 16/03/18 20:54
−42
−
Number of Pharmaceutical Approvals Granted in Japan
Japan
Note : In the revised Japan’s Pharmaceutical Affairs Law of April 1, 2005, “Manufacturing Approval” and “Import Approval” were replaced by Marketing Approval .
Source : Until 2004, The Yakuji Nippo, Recent New Drugs From 2005, Jiho, Yakuji Handbook
FiscalYear
Ethical Drugs OTC DrugsManufacturing
ApprovalImport
ApprovalMarketingApproval Total Manufacturing
ApprovalImport
ApprovalMarketingApproval Total
FiscalYear
Ethical Drugs OTC DrugsManufacturing
ApprovalImport
Approval Total ManufacturingApproval
ImportApproval Total
1_03_研究開発の現況_eng.indd 42
16/03/18 20:54
− 43 −
Number of Pharmaceuticals Included in the NHI Price List in Japan
Japan
Fiscal Year Internal Injections External DentalDrugs Total
Source : Ministry of Health, Labour and Welfare, Notice by Health Insurance Bureau
1_03_研究開発の現況_eng.indd 43 16/03/18 20:54
− 44 −
Number of New Molecular Entities Approved
Japan as of the end of November 2015
ManufacturingApproval
ImportApproval
SalesApproval
Note : 1. In vitro diagnostics, insecticides, and OTC products are excluded. 2. The numbers with an asterisk in the total column are less than the sum of Approval numbers as some drugs contain the same ingredients.
Source : Until 1986, The Society of Japanese Pharmacopoeia, Drug Approval and Licensing Procedures in Japan From 1987, Yakumu Kohosha, Yakumu Koho
Year No. of New Drugs New Molecular Entities
Total
1_03_研究開発の現況_eng.indd 44 16/03/18 20:54
− 45 −
Number of New Molecular Entities ApprovedJapan Accumulation from 2000 to 25 Nov. 2014
ManufacturingApproval
ImportApproval
A A A B Pfizer GlaxoSmithKline MSD Novartis Bayer Chugai Sanofi Janssen Astellas Mitsubishi Tanabe Kyowa Hakko Kirin Takeda Daiichi Sankyo AstraZeneca Eli Lilly Dainippon Sumitomo Ono Shionogi Eisai Novo Nordisk Genzyme Boehringer Ingelheim Kyorin PharmaBristol-Myers AbbVie Otsuka Meiji Seika Pharma Japan Tobacco Nippon Shinyaku Nippon Kayaku Baxalta Toyama Chemical Kissei
Note : 1. Accumulative number of JPMA Member Companies top 33. 2. Approval until 25 Nov. 2015 are listed. (A) Approval until 25 Nov. 2014. (B) Approval from Jan. 2015 to 25 Nov. 2015. 3. The figure for AbbVie Inc. includes data for the former Abbott Japan. The figure for Baxalta includes data for the former Baxter.
Source : Yakumu Kohosha, Yakumu Koho
Company Total SalesApproval
1_03_研究開発の現況_eng.indd 45 16/03/18 20:54
− 46 −
Success Rate of Developing New Drugs in Japan
. Low Molecular Weight Compounds
1) Success rate for 5 years 2010 2014
Phase
Synthesized Compounds
Pre-Clinical Studies Started Clinical Studies Started in Japan
Approval Granted
2) Trends by Fiscal Year
Item
Synthesized Compounds
Pre-Clinical Studies Started Clinical Studies Started in Japan
Approval Granted
Number of Companies
. Biologicals
AntibodyDrugs
OtherDrugs*
AntibodyDrugs
OtherDrugs*
AntibodyDrugs
OtherDrugs*
Pre-Clinical Studies Started Clinical Studies Started in Japan
Approval Granted
Number of Companies
*Including nucleic acid medicine and peptide.Note : Survey was started in FY2012.
Source : JPMA Survey (Data obtained from domestic companies of the R&D Committee members.)
No. of Chem. Entity Probability to Movefrom Previous Phase Success Rate
Item
Note : 1. Chemical libraries (such as combinatorial chemistry) are not included in Synthesized Compounds. 2. Only the compounds of in-house (excl. in-licensing). Additional dosage forms and indications are excluded.
1_03_研究開発の現況_eng.indd 46 16/03/18 20:54
− 47 −
Median Development Times for New Molecular Entities
Number ofApprovals
MedianDevelopment
Time Months
Number ofApprovals
MedianDevelopment
Time Months
Number ofApprovals
MedianDevelopment
Time Months
Note : 1. Development time is the period from initial protocol application to the approval date. 2. Standard review products include accelerated approval products.
Source : From 2000, Office of Pharmaceutical Industry Research of JPMA, Research Paper Series No.68 “Research on trend of time period for Clinical Development and Review Procedures for New Drugs approved in Japan”
by NDA approval year
YearNDA approved
All Products Priority Review Products Standard Review Products
1_03_研究開発の現況_eng.indd 47
16/03/18 20:54
−48
−
Median Approval Times for New Drugs
by NDA filing year
Number ofApplications
Median ApprovalTime Months
Number ofApplications
Median ApprovalTime Months
Number ofApplications
Median ApprovalTime Month
Note: 1. About products filed for NDA since 2012, they have some pending items hence it does not include counting in this table. Further information should be required to evaluate this table totally. 2. Researched items are the products in which approved from 2000 to 2014. (From 2000 to 2004: Product items for Subcommittee of Pharmaceutical Affairs and Food Sanitation Council, and After 2005: Product items for Subcommittee of Pharmaceutical Affairs and Food Sanitation Council, plus its reported items) 3. Standard review products include accelerated approval products.
Source : Office of Pharmaceutical Industry Research of JPMA, Research Paper Series No.68 “Research on trend of time period for Clinical Development and Review Procedures for New Drugs approved in Japan”
YearNDA filed
All Products Priority Review Products Standard Review Products
1_03_研究開発の現況_eng.indd 48
16/03/18 20:54
− 49 −
MHLW(Ministry of Health, Labour and Welfare)
Appointment/Appointment/ConsultationConsultation
AdviceAdvice
Pharmaceuticals and Medical Devices Agency (PMDA)
External experts
External expertsand
Team reviewCompliance review
Review report①
Review report②
GMP auditManufacturing site
Withdrawal request
Withdrawal request
Expert Discussion on Review Ⅰ
Discussion on main issues and conclusionDocument -based discussion possible
Summary of main issues
Expert Discussion on Review Ⅱ
GMP compliance audit result( result notification )
Report onreview result
( review result notification )
Approval Consultation
AdviceDisapproval
Pharmaceutical Affairsand Food SanitationCouncil
Applicant
Interviewand
Inquiry and confirmation from PMDAPresentation from the applicant and response
ApplicantReviewers
Reviewers
Investigators
and
Interview Review Meeting
Opportunity for applicant to explain (presentation ) Consider main issues Conducted by Office Director (or Review Director )
Reviewers
External expertsSpecialist on the applicant side
Applicant
Continue after interview review
External expertsandReviewers
Review Process for Approval
1_03_研究開発の現況_eng.indd 49 16/03/18 20:54
−50
−
Trends in Notification of Clinical Trials
Initial
Notificationon NMEs
Initial Notificationon New Administration Routeand New Ethical Combination
Notificationof nth time
Notificationof Change
Notificationof Completion
Notificationof Suspension
Notificationof Development
Suspension
FYFYFYFYFYFYFYFYFYFYFYFYFY
Note: 1. Regarding 1997 data, this is combined of the data from existing "Clinical Trial Plan Notification" (CTPN) until March, 1997, and the data of those after “Revision of Pharmaceutical Affairs Act" effectively since April 1997. 2. "Notification of "n"th time" represents on and after 2nd time of CTPN. 3. About "Notification of Completion", it was formerly allowed submitting each Clinical Trial Plan and/or all Clinical Trial Plans. It is currently only allowed submitting each Clinical Trial Plan respectively, since April 1997. 4. "Notification of Development Suspension" is required its submission since April 1997. 5. Data for 2013 have been revised in accordance with changes in quoted sources.
Source : Yakumu Kohosha, Yakumu Koho
Initial Notification
1_03_研究開発の現況_eng.indd 50
16/03/18 20:54
− 51 −
Number of Drug Patents
Japan
A DomesticApplicants
ForeignApplicants
Note : The total number of patents : Until 1995, the total number of disclosed patents From 1997, the number of registered patent publications
Counted by the International Patent Classification A61P Therapeutic Activity of Chemical Compounds or Medicinal Preparations .
Source : Until 1999, Japan Patent Information Organization From 2000 to 2012, Patent On-Line Information System PATOLIS 2013-, JP-Net
YearNo. of Drug Patents
Total No. ofPatents B
Ratio to TotalNo. of Patents
A/B %
1_03_研究開発の現況_eng.indd 51 16/03/18 20:54
−52
−
Number of Drug Patents in Japan
Japanese Companies
Meiji Seika Taisho
Sankyo Daiichi
Kowa Otsuka
Yamanouchi Fujisawa Sumitomo Dainippon
Takeda Shionogi Ajinomoto Taiho
Kyowa Hakko Kirin Welfide Mitsubishi Chemical etc. Tanabe
Santen Chugai Toray Eisai Ono Nippon Chemiphar Asahi Kasei
Note : Counted by the International Patent Classification A61P Therapeutic Activity of Chemical Compounds or Medicinal Preparations .
Source : 2000 to 2012, Patent On-Line Information System PATOLIS 2013, JP-Net
Company \ Year
Daiichi Sankyo
Mitsubishi Tanabe
Dainippon Sumitomo
Kyowa Hakko Kirin
Astellas
1_03_研究開発の現況_eng.indd 52
16/03/18 20:54
− 53 −
Number of Drug Patents in Japan
Foreign Companies
Roche Novartis Alcon
GlaxoSmithKline Boehringer Ingelheim
Aventis Sanofi-Synthelabo Genzyme Merck Schering-Plough Organon Bayer Schering AG
Johnson & Johnson Avvie (- '13;Abbott)
Pfizer Wyeth
Bristol-Myers Squibb Allergan Baxalta (Baxter) Merck (Germany) Amgen Gilead Sciences Novo Nordisk Celgene AstraZeneca Eli Lilly
Note : Counted by the International Patent Classification A61P Therapeutic Activity of Chemical Compounds or Medicinal Preparations .
Source : 2000 to 2012, Patent On-Line Information System PATOLIS 2013-, JP-Net
Company \ Year
Merck USA
Novartis
Pfizer
Sanofi
Bayer
1_03_研究開発の現況_eng.indd 53
16/03/18 20:54
− 54 −
Number of Bio-technology Patents
Area \ Year
Japan
U.S.A.
Europe
Others
Total
Note : Europe includes 5 countries, namely, the UK, Germany, France, Switzerland and the Netherlands.International Patent Classification C12N15/00
Adjusted and counted by Convention Priority Right countries.
Source : JP-Net
Number of Published Patent Applications in Japanby Applicant's Nationality
0
500
1,000
1,500
2,000
2,500
Japan
U.S.A.
Europe
Others
1_03_研究開発の現況_eng.indd 54 16/03/18 20:54
− 55 −
Technology Exports and Imports in the Pharmaceutical Industry
Japan
Cases Value Cases Value Cases Value Cases Value Cases Value Cases Value
Source : Ministry of Internal Affairs and Communications, Report on the Survey of Research and Development , http://www.e-stat.go.jp/SG1/estat/GL08020103.do?_toGL08020103_&tclassID=000001051223&cycleCode=0&requestSender=search
Contracts with Parent / Affiliated Company
Unit : JPY mil.
FiscalYear
Total Contracts New ContractsRevenue Payment Balance Revenue Payment Balance
1_03_研究開発の現況_eng.indd 55
16/03/18 20:54
— INTERNATIONAL STATISTICS —
Ⅰ . Pharmaceutical Industry Outlook
INT
ERN
ATIO
NA
L ST
ATIS
TIC
S
Ⅰ. P
harm
aceu
tica
l Ind
ustr
y O
utlo
ok
扉_eng.indd 4 16/03/18 20:52
− 59 −
Number of Pharmaceutical ManufacturersMajor Countries
Year \ Country U.S.A. Germany U.K. Switzerland France Italy Spain
Source : Associazione delle imprese del farmaco, “Evoluzione del settore farmaceutico” U.S. Census Bureau, “Statistics of U.S. Businesses - Pharmaceutical preparation mfg” http://www.census.gov/econ/susb/
2_01_医薬品産業の現況_eng.indd 59
16/03/18 20:54
− 60 −
Employment in the Pharmaceutical Industry
Europe
Country
Austria
Belgium
Denmark
Finland
France
Germany
Greece
Ireland
Italy
Netherlands
Norway
Portugal
Spain
Sweden
Switzerland
U.K.
Total
Source : EFPIA, The Pharmaceutical Industry in Figures , http://www.efpia.eu/
2_01_医薬品産業の現況_eng.indd 60 16/03/18 20:54
− 61 −
Pharmaceutical MarketSales by Geographic Region Unit : USD bil., %
Sales Share Sales Share Sales Share Sales Share Sales Share
North America
Japan
Germany
France
Italy
U.K.
Other Europe
Central / South America
Asia-Pacific excluding Japan , Africa and Middle East
World Total
Source : Calculated based on IMS World Review 2015 (Reprinted with permission)
2016 IMS Health. All rights reserved.
Country
2_01_医薬品産業の現況_eng.indd 61
16/03/18 20:54
− 62 −
Concentration on Pharmaceutical Sales to Leading Companies
Worldwide 2014 from January to December Unit : USD mil., %
Value Share Value Share 1st 10th
11th 20th21st 30th31st 40th41st 50th51st 60th61st 70th71st 80th81st 90th
91st 100thOthers
Total 100+Others
Source : Calculated based on IMS World Review 2015 (Reprinted with permission)
Change in the concentration on Leading Companies Unit : %
Fiscal Year 10 LeadingCompanies
20 LeadingCompanies
30 LeadingCompanies
50 LeadingCompanies
Fiscal Year 10 LeadingCompanies
20 LeadingCompanies
30 LeadingCompanies
50 LeadingCompanies
Source : from 2000 to 2005, SCRIP, Pharmaceutical Company League Tables
Calculated based on IMS World Review 2015 (Reprinted with permission)
Order by SalesTotal Sales Cumulative
2016 IMS Health. All rights reserved.
from 2005 to 2014, 2016 IMS Health. All rights reserved.
2_01_医薬品産業の現況_eng.indd 62 16/03/18 20:54
− 63 −
Operating Results of Leading Pharmaceutical Manufacturers
Worldwide 2014 including Japanese manufacturers
% %
Novartis USD mil. Pfizer USD mil. Sanofi EUR mil. Roche CHF mil. Merck USA USD mil. Johnson & Johnson USD mil. GlaxoSmithKline GBP mil. AstraZeneca USD mil. Gilead Sciences USD mil. AbbVie USD mil. Amgen USD mil. Teva USD mil. Eli Lilly USD mil. Baxter USD mil. Bayer EUR mil. Takeda JPY bil. Bristol-Myers Squibb USD mil. Novo Nordisk DKK mil. Boehringer Ingelheim EUR mil. Astellas JPY bil. Merck Germany EUR mil. Daiichi Sankyo JPY bil. Otsuka Holdings JPY bil. Abbott USD mil. Mylan USD mil. Eisai JPY bil.
Note : Abbott Laboratories (Abbott) separated into two publicly traded companies in 2013, as AbbVie and Abbott. Enumeration data for each company is showed in this table. The number of employees of Amgen, Baxter, and Boehringer Ingelheim are data for 2013. Ordinary income for Otsuka Holdings only.
Source : SPEEDA (UZABASE, Inc.), Annual reports, and Financial statements
Net Income No.ofEmployeesCompany Currency Total
SalesPharmaSales
%PharmaSales
PharmaSales byUSD mil.
Pretax Income* TotalAssets
2_01_医薬品産業の現況_eng.indd 63
16/03/18 20:54
−64
−
Financial Results of Leading Pharmaceutical Manufacturers
Worldwide 2014 including Japanese manufacturers
% Novartis USD mil. Pfizer USD mil. Roche CHF mil. Merck USA USD mil. Johnson & Johnson USD mil. Sanofi EUR mil. GlaxoSmithKline GBP mil. AstraZeneca USD mil. Gilead Sciences USD mil. AbbVie USD mil. Amgen USD mil. Teva USD mil. Eli Lilly USD mil. Baxter USD mil. Bayer EUR mil. Takeda JPY bil. Bristol-Myers Squibb USD mil. Novo Nordisk DKK mil. Boehringer Ingelheim EUR mil. Astellas JPY bil. Merck Germany EUR mil. Daiichi Sankyo JPY bil. Otsuka Holdings JPY bil. Abbott USD mil. Mylan USD mil. Eisai JPY bil.
Note : Abbott Laboratories (Abbott) separated into two publicly traded companies in 2013, as AbbVie and Abbott. Enumeration data for each company is showed in this table.
Source : SPEEDA(UZABASE Inc.), Annual reports, Financial statements
EquityRatio %
Return onAsset %
Return onEquity %Company Currency Net
IncomeTotal
Assets EquityTotalSales
2_01_医薬品産業の現況_eng.indd 64
16/03/18 20:54
− 65 −
Profitability of Research-based Companies
U.S.A. and Europe 2014
Currency TotalSales
NetIncome
Return onAsset %
Return onEquity %
Net IncomeMargin %
Pfizer USD mil. Merck USD mil. Eli Lilly USD mil. General Electric GE USD mil. Ford Motor USD mil. IBM USD mil. Texas Instruments USD mil. Motorola USD mil. ITT USD mil. Novartis USD mil. Roche CHF mil. Bayer EUR mil. Sanofi EUR mil. AstraZeneca USD mil. GlaxoSmithKline GBP mil. Volkswagen EUR mil. Daimler Chrysler EUR mil. BASF EUR mil. Siemens EUR mil.Nokia EUR mil.
Source : Annual reports, SPEEDA(UZABASE Inc.)
U.S.A.
Pharmaceuticals
Other Industries
Europe
Pharmaceuticals
Other Industries
2_01_医薬品産業の現況_eng.indd 65
16/03/18 20:54
−66
−
International Trade of Pharmaceutical Products
Major Countries Unit : USD mil. Country
Year
Austria
Belgium
Denmark
Finland
France
Germany
Greece
Ireland
Italy
Netherlands
Norway
Portugal
Spain
Sweden
Switzerland
U.K.
Canada
U.S.A.
Japan
Others
Total OECD
Source : OECD, International Trade by Commodities Statistics Classification No.54
Exports Imports Surplus
2_01_医薬品産業の現況_eng.indd 66
16/03/18 20:54
− 67 −
Exports of Pharmaceutical Products by Partner Country
Worldwide 2013 Unit : USD thousandExporter
Importer Austria Belgium Denmark France Germany Ireland Italy Netherlands Spain Sweden Switzerland U.K. U.S.A. Canada Australia Japan Others World Total
Exporter Importer Austria Belgium Denmark France Germany Ireland Italy Netherlands Spain Sweden Switzerland U.K. U.S.A. Canada Australia Japan Others World Total
Source : OECD, International Trade by Commodities Statistics Classification No.54
Italy Netherlands
Spain Sweden Switzerland U.K. U.S.A. Canada Australia Japan
Austria Belgium Denmark France Germany Ireland
2_01_医薬品産業の現況_eng.indd 67
16/03/18 20:54
−68
−
Imports of Pharmaceutical Products by Partner Country
Worldwide 2013 Unit : USD thousandImporter
Exporter Austria Belgium Denmark France Germany Ireland Italy Netherlands Spain Sweden Switzerland U.K. U.S.A. Canada Australia Japan Others World Total
Importer Exporter Austria Belgium Denmark France Germany Ireland Italy Netherlands Spain Sweden Switzerland U.K. U.S.A. Canada Australia Japan Others World Total
Source : OECD, International Trade by Commodities Statistics Classification No.54
Italy Netherlands
Spain Sweden Switzerland U.K. U.S.A. Canada Australia Japan
Austria Belgium Denmark France Germany Ireland
2_01_医薬品産業の現況_eng.indd 68
16/03/18 20:54
− 69 −
Overseas Sales of Leading Pharmaceutical Manufacturers
Worldwide excluding Japanese manufacturers
Percentageof Sales
Percentageof Sales
Percentageof Sales
Percentageof Sales
Novartis USD mil. Pfizer USD mil. Roche CHF mil. Merck (USA) USD mil. Johnson & Johnson USD mil. Sanofi EUR mil. GlaxoSmithKline GBP mil. AstraZeneca USD mil. Gilead Sciences USD mil. AbbVie USD mil. Abbott USD mil. Amgen USD mil. Teva USD mil. Eli Lilly USD mil. Baxter USD mil. Bayer EUR mil. Bristol-Myers Squibb USD mil. Novo Nordisk DKK mil. Boehringer Ingelheim EUR mil. Merck (Germany) EUR mil. Mylan USD mil.
Note : Abbott Laboratories (Abbott) separated into two publicly traded companies in 2013, as AbbVie and Abbott. The data since 2011 for each company is showed in this table.
Overseas sales includes the sales figures of pharmaceuticals and non-pharmaceuticals. *1 : Outside Europe *2 : Outside Switzerland *3 : Europe and North America Teva is an Israeli company *4 : Outside UK *5 : Outside France *6 : Outside Germany
Source : Annual reports
OverseasSales
OverseasSales
OverseasSales
OverseasSales
Manufacturer Currency
2_01_医薬品産業の現況_eng.indd 69
16/03/18 20:54
−70
−
Miscellaneous IndexesTable 1 Table 2 Table 3
CompanyIncome before tax*
No. of Employees1000 $
Industry CompanyLiquidityRatio* Company
Aggregate MarketValue of stock***
bil $ Astellas Otsuka Holdings Takeda Otsuka Holdings Daiichi Sankyo Astellas Daiichi Sankyo Astellas Daiichi Sankyo Eisai Eisai Eisai Takeda Takeda Mitsubishi Tanabe Amgen Amgen Johnson & Johnson Merck (USA) Pfizer Pfizer Johnson & Johnson Sanofi Merck (US)Pfizer Merck (US) AmgenBristol-Myers Squibb Novartis AbbVie AbbVie GlaxoSmithKline BMSEli Lilly Canon Eli Lilly Baxter Nissan Baxter Novo Nordisk Richo Novartis Roche NEC Roche Novartis Panasonic Sanofi Sanofi Fujitsu Bayer Merck (Germany) Hitachi GlaxoSmithKline Bayer Honda Novo Nordisk B. Ingelheim Toshiba AstraZeneca GlaxoSmithKline Toyota Merck (Germany) AstraZeneca Sony
Texas Instruments * Closing price for the end of December 2014 * The figure for Otsuka Holdings is ordinary income. ITT Industries at each stock exchange.
NokiaSource : Annual reports, Financial statements BASF Source: SPEEDA (UZABASE, Inc.) Siemens
IBM
Source : SPEEDA (UZABASE, Inc.)
Japan
U.S.A.
Europe
Japan
U.S.A.
Europe
* Liquidity Ratio=Current Assets/Current Liabilities
Foreign Non-Pharmaceutical Industries
Japanese Pharmaceutical Manufacturers
Foreign Pharmaceutical Manufacturers
Japanese Non-Pharmaceutical Industries
2_01_医薬品産業の現況_eng.indd 70
16/03/18 20:54
— INTERNATIONAL STATISTICS —
Ⅱ . Pharmaceutical Research and Development
INT
ER
NAT
ION
AL
ST
ATIS
TIC
S
Ⅱ. P
harm
aceu
tica
l Res
earc
h
a
nd D
evel
opm
ent
扉_eng.indd 5 16/03/18 20:52
− 73 −
R&D Expenditures of Leading Pharmaceutical Manufacturers
Worldwide excluding Japanese manufacturers
Expendi-tures
Change%
R&D/Sales
%
Expendi-tures
Change%
R&D/Sales
%
Expendi-tures
Change%
R&D/Sales
%
Expendi-tures
Change%
R&D/Sales
%
Expendi-tures
Change%
R&D/Sales
% Novartis USD mil. Pfizer USD mil. Roche CHF mil. Merck USA USD mil. Johnson & Johnson USD mil. Sanofi EUR mil. GlaxoSmithKline GBP mil. AstraZeneca USD mil. Gilead Sciences USD mil. AbbVie USD mil. Abbott USD mil. Amgen USD mil. Teva USD mil. Eli Lilly USD mil. Baxter USD mil. Bayer EUR mil. Bristol-Myers Squibb USD mil. Novo Nordisk DKK mil. Boehringer Ingelheim EUR mil. Merck Germany EUR mil. Mylan USD mil.
Note : 1. Pfizer merged Wyeth in 2009. 2. Merck (USA) merged with Schering-Plough in 2009. 3. Abbott Laboratories (Abbott) separated into two publicly traded companies in 2013, as AbbVie and Abbott. The data since 2011 for each company is showed in this table.
Source : Annual reports
Company Currency
2_02_研究開発の現況_eng.indd 73
16/03/18 20:55
−74
−
R&D Expenditures by Developmental Stage
U.S.A.
ExpendituresUSD mil.
ExpendituresUSD mil.
ExpendituresUSD mil.
ExpendituresUSD mil.
Prehuman / Preclinical
Phase
Phase
Phase
Approval
Phase
Subtotal
Uncategorized
Total
Source : PhRMA, Pharmaceutical Industry Profile , http://www.phrma.org/profiles-reports
Percentage%
Percentage%
Percentage%
Percentage%
2_02_研究開発の現況_eng.indd 74
16/03/18 20:55
− 75 −
1,411
904
1,100
1,272
1,565
1,900
2,310
2,490
2,619
3,115
3,482
3,692
4,069
4,375
4,486
4,894
6,045
5,898
5,7985,717
5,847
15.816.4
15.9 16.116.6
17.8
16.517.2
18.2
18.2
15.2
16.617.0
16.2
26.2
21.8
19.6
10.211.0
10.6 10.7
10.711.4 11.4
13.313.8
14.2
16.2
15.9 15.415.2
11.3
12.2
14.9
15.1
15.1
16.9
17.7
22.3
20.2
14.7 15.0
Trends of R&D Expenditures and Profits as Sales Ratio
Note : 1. Companies surveyed: Abbvie & Abbott (as former Abbott), Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck and Pfizer.
Number of companies surveyed:2. 1991 to 1998: 10 companies (excluded Amgen, Wyeth and included AHP (currently Wyeth),
Upjohn, Warner Lambert)3. 1999, and 2003 to 2005: 8 companies (excluded Amgen)4. 2000 to 2002: 9 companies (excluded Amgen, included Pharmacia)5. From 2009: 7 companies (Merck incorporated Schering-Plough, Pfizer acquired Wyeth)6. In 2013, Abbott Laboratories (Abbott) separated into two publicly traded companies as Abbott
and AbbVie.The enumeration data as of 2013 is combined both of two companies' data as one firm.
Source : Annual Report
U.S.A(7 companies)R&D Expenditures per Company(Average of 7 companies)
Net Profit Margin (%)
R&D Expenditures per Sales (%)
(year)
020111994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2009 20102008
4,600
4,500
4,400
4,300
5,000
4,900
4,800
4,700
4,200
4,100
5,600
5,500
5,400
5,300
6,000
5,900
5,800
5,700
5,200
5,100
4,000
3,900
3,800
3,700
3,600
3,500
3,400
3,300
3,200
3,100
3,000
2,900
2,800
2,700
2,600
2,500
2,400
2,300
2,200
2,100
2,000
1,900
1,800
1,700
1,600
1,500
1,400
1,300
1,200
1,100
1,000
900
800
700
600
USD mil.
%40
35
30
25
20
15
10
5
02012 2013 2014
7. 2014: AbbVie, Amgen, Bristol-MyersSquibb, EliLilly, Johnson&Johnson, Merck, Pfizer.
2_02_研究開発の現況_eng.indd 75 16/03/18 20:55
− 76 −
Published PCT Applications by Pharmaceutical Company
Company Abbott Abbott Laboratories Amgen Amgen AstraZeneca AstraZeneca AB
Bayer Pharmaceutical Corp. Bayer Pharma AG. Bayer CropScience Bayer Schering Pharma AG Bayer HealthCare Schering Aktiengesellshaft
B.Ingelheim Boehringer Ingelheim Intn'l GmbH BMS Bristol-Myers Squibb Co. Eli Lilly Eli Lilly and Co.
Glaxo Group Ltd. SmithKline Beecham Corp. GlaxoSmithKline LLC GlaxoSmithKline Biological S.A. GlaxoSmithKline Intellectual Property Janssen Pharmaceutica N.V. Centocor, Alza Corp. Alza Corp.
Merck Germany Merck Patent GmbH Schering-Plough Merck & Co.,Inc. Organon Merck Sharp and Dohme Corp Novartis AG Alcon, Chiron Corp.,
Novo Nordisk Novo Nordisk A/S Pfizer Inc. Pfizer Ltd. Pfizer Products Inc. Warner-Lambert Co. Pharmacia & Upjohn Co. Pharmacia Corp. Wyeth F.Hoffmann-La Roche AG Genentech,Inc. Sanofi Sanofi-Aventis Sanofi-Aventis Deutschland GmbH Aventis Pharma S.A. Genzyme
Teva Teva Pharmaceutical Industries, Ltd.
Note : Non-pharmaceutical patents are included.
Source : Until 2012, WIPO/PCT Patents Fulltext, and Derwent World Patents Index(DWPI) is used only for Warner-Lambert Co. 2013-, JP-Net Overseas
Daiichi Sankyo Sankyo/Daiichi Pharma Asubio Pharmaceuticals,Inc Daiichi Suntory, Daiichi Asubio Takeda Chemical Industries, Ltd. Takeda Pharma
Sanofi
Bayer
Merck USA
Roche
Novartis
Pfizer
Johson & Johson
GSK
Astellas
Eisai Eisai Eisai/Eisai R&D Management
Daiichi Sankyo
Takeda
Astellas Pharma Inc. Yamanouchi Pharma/Fujisawa Pharma
2_02_研究開発の現況_eng.indd 76 16/03/18 20:55
Statistics on Health Care
Stat
isti
cs o
n H
ealt
h C
are
扉_eng.indd 6 16/03/18 20:52
− 79 −
Life Expectancy
Japan Unit : Years
Year
Age
Source : Ministry of Health, Labour and Welfare, Abridged Life Table , http://www.mhlw.go.jp/toukei/saikin/hw/seimei/list54-57-02.html
Male Female
3_参考資料_eng.indd 79 16/03/18 20:55
− 80 −
Life Expectancy
Worldwide Unit : Years
Area Country Period Male Female Period Male Female
Asia Japan
Israel
India
Indonesia
Korea
China
Europe Iceland
Italy
U.K.
Austria
Netherlands
Switzerland
Sweden
Czech Republic
Denmark
Germany
Norway
Finland
France
Russia
North America U.S.A.
Canada
Mexico
South America Argentina
Brazil
Africa Egypt
South Africa
Oceania Australia
New Zealand
Source : Ministry of Health, Labour and Welfare, Abridged Life Table , http://www.mhlw.go.jp/toukei/saikin/hw/seimei/list54-57-02.html
United Nations, Statistics Division, Demographic Yearbook , http://unstats.un.org/unsd/default.htm
3_参考資料_eng.indd 80 16/03/18 20:55
− 81 −
Trends of Vital Statistics
JapanLive
Births Deaths NaturalChange
InfantDeaths
NeonatalDeaths
Note : No data available for 1945.
Source : Ministry of Health, Labour and Welfare, Vital Statistics , http://www.mhlw.go.jp/toukei/list/81-1a.html
Yearper 1,000 Population per 1,000 Births
3_参考資料_eng.indd 81 16/03/18 20:55
− 82 −
Trends of Vital Statistics Foreign Countries
LiveBirths Deaths Infant
DeathsNeonatalDeaths
LiveBirths Deaths Infant
DeathsNeonatalDeaths*
Source : United Nations, Statistics Division, Demographic Yearbook *UNICEF, Child Mortality Estimates
Canada
U.S.A.
Mexico
Brazil
Australia
Argentina
New Zealand
U.K.
Switzerland
Russia
Sweden
Germany
Norway
Italy
Netherlands
France
Czech Rep.
Finland
Denmark
Austria
Egypt
Israel
Country
per 1,000 Populat. per 1,000 Births per 1,000 Populat. per 1,000 Births
Indonesia
Korea
China
India
3_参考資料_eng.indd 82 16/03/18 20:55
− 83 −
Mortality Rate by Major Causes
Japan
Year
Source : Ministry of Health, Labour and Welfare, Vital Statistics , http://www.mhlw.go.jp/toukei/list/81-1a.html
Malignant Neoplasms
Stomach
Liver
Trachea, Bronchus & Lung
Diabetes
Hypertensive disease
Suicides
Cerebrovascular Disease
Pneumonia
Hepatic disease
Renal disease
Senility without psychosis
Accidents
Heart disease excluding hypertensive heart disease
Causes of Death
Total
Tuberculosis
Deaths Deaths per 100,000 population
3_参考資料_eng.indd 83
16/03/18 20:55
−84
−
Mortality Rate by Major Causes
Cross Countries Comparison, 2013 Unit : Per 100,000 population
(2011) (2011)
France France
Total Deaths Total Mortality Rate Tuberculosis Malignant Neoplasms Esophagus Stomach Colon, Rectosigmoid Junction, Rectum & Anus Liver Trachea, Bronchus & Lung Prostate Breast Female Cervix Uteri Lymphoid, Leukemia & Haematopoietic tissue Diabetes Hypertensive Disease Ischaemic Heart Diseases Cerebrovascular Diseases Pneumonia Gastric & Duodenal Ulcer Diseases of the Liver Disorders of Kidney and Ureter Transport Accidents Intentional Self-Harm
Source : United Nations, Statistics Division, Demographic Yearbook , http://unstats.un.org/unsd/default.htm
GermanyJapan Japan
FemaleCause of Death
Male
U.S.A. U.K. Germany U.S.A. U.K.
3_参考資料_eng.indd 84
16/03/18 20:55
− 85 −
National Health Care Expenditures
Japan
Value Change%
per Capita1,000 Yen
Change%
Percentageof GDP
Percentageof National
Income
Note : Long-term care insurance cost was excluded since 2000.
Source : Ministry of Health, Labour, and Welfare, Estimates of National Medical Care Expenditure , http://www.mhlw.go.jp/toukei/list/37-21c.html Economic and Social Research Institute, Cabinet Office, Annual Report on National Accounts , http://www.esri.cao.go.jp/jp/sna/menu.html
FiscalYear
National Health Care Expenditures Proportion of NationalHealth Care Expenditures
3_参考資料_eng.indd 85 16/03/18 20:55
−86
−
National Health Care Expenditures
Major Countries Unit : USD mil.Country \ Year
Australia Austria Belgium Canada Denmark France Germany Ireland Italy Japan Korea Luxembourg Netherlands Norway Portugal Spain Sweden Switzerland United Kingdom United States
*Figures may differ from those of past DATA BOOKs due to revision in accordance with changes in data in the quoted sources.
Source : OECD, OECD Health Data
3_参考資料_eng.indd 86
16/03/18 20:55
− 87 −
National Health Care Expenditures %GDP
Major CountriesCountry \ Year
Australia Austria Belgium Canada Denmark France Germany Ireland Italy Japan Korea Luxembourg Netherlands Norway Portugal Spain Sweden Switzerland United Kingdom United States
*Figures may differ from those of past DATA BOOKs due to revision in accordance with changes in data in the quoted sources.
Source : OECD, OECD Health Data
3_参考資料_eng.indd 87
16/03/18 20:55
−88
−
National Health Care Expenditures and Share by Source of Revenues
Japan
JPY bil.
GDP %
1,000 Yen
Nation
Prefectures
Employer
Employee
Note : 1. Until 1995, Percentage of GDP was the GNP ratio. 2. Long-term care insurance cost was excluded since 2000.
Source : Ministry of Health, Labour and Welfare, Estimates of National Medical Care Expenditure , http://www.mhlw.go.jp/toukei/list/37-21c.html GDP : Economic and Social Research Institute, Cabinet office, Annual Report on National Accounts , http://www.esri.cao.go.jp/jp/sna/menu.html
Source ofRevenue
%
Public Expenses
Health Insurance
Out of pockets
Others
Fiscal Year
NationalHealthCare
Expend.
Total
Percentage of
per Capita
3_参考資料_eng.indd 88
16/03/18 20:55
− 89 −
National Health Care Expenditures and Share by Source of Revenues
U.S.A.
Federal
State & Local
Note : 1. National Health Care Expenditure are Personal Health Care which is equivalent to Japanese National Health Care Expenditure. 2. The ratio to GDP and medical treatment expenses per capita are calculated based on National Health Expenditure in NHE Web tables of CMS data. 3. Insurance Premium includes only Private Health Insurance. Data for the 2014 Source of Revenue (%) have been revised.
Source : CMS, National Health Expenditures by type of service and source of funds , NHE Web tables , http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html
Year
NationalHealthCare
Expend.
Total
Percentage of GDP
USD
USD bil.
% per Capita
Source ofRevenue
%
Government
Insurance Premium
Out of pockets
Others
3_参考資料_eng.indd 89
16/03/18 20:55
−90
−
Proportion of National Treasury Expenses in National Health Care Expenditures
Japan Unit : JPY bil.
FiscalYear
General AccountsBudget
A
National HealthCare Expenditures
B
National TreasuryExpenses in B
C C / A % C / B %
* Data published in past DATA BOOK have been revised.
Source : National Health Care Expenditures : Ministry of Health, Labour and Welfare, Estimates of National Medical Care Expenditure , http://www.mhlw.go.jp/toukei/list/37-21c.html General Accounts Budget : Ministry of Finance Japan, Budget , http://www.mof.go.jp/budget/budger_workflow/budget/index.html
3_参考資料_eng.indd 90
16/03/18 20:55
− 91 −
Proportion of National Treasury Expenses in National Health Care Expenditures
U.S.A. Unit : USD bil.
YearGeneral Accounts
BudgetA
National Health CareExpenditure
B
National TreasuryExpense in B
CC / A % C / B %
Note: 1. National Health Care Expenditure are Personal Health Care which is equivalent to Japanese National Health Care Expenditure. 2. National Treasury Expense represent the expense of the Federal Government. 3. Datum for 2012 (c) has been revised.
Source : National Health Care Expenditure : CMS, National Health Expenditures by type of service and source of funds ,
http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/ NationalHealthAccountsHistorical.html National Treasury Expense :
Until 1997, Bank of Japan, Comparative Economic and Financial Statistics Japan and Other Major Countries From 1998 to 2002, Toyo Keizai, Economic Statistic Almanac From 2003, United States Department of the Treasury, Joint Statement on Budget Results for Fiscal Year ,
http://search.treasury.gov/search?affiliate=treasury&commit=Search&query=Table%203.--OUTLAYS%202012
3_参考資料_eng.indd 91
16/03/18 20:55
−92
−
Social Benefit
Social Benefit by Category and the Percentage of National Income Japan
Source : National Institute of Population and Social Security Research, The Financial Statisics of Social Security in Japan FY2013 , http://www.ipss.go.jp/ss-cost/j/fsss-h25/fsss_h25.asp
Percentageof
NationalIncome
Medical Care
Pensions
Welfare & Others
Long-term Care
Total
ValueJPY bil.
Category
Medical Care
Pensions
Welfare & Others
Long-term Care
Total
3_参考資料_eng.indd 92
16/03/18 20:55
− 93 −
Number of Medical Care FacilitiesJapan
Number of Facilities
Total Hospitals Psychiatric Hospitals Infectious Dis. Hospitals Tuberculosis Sanatoria General Hospitals Comprehensive Hospitals re-sum General Practitioners With Beds Without Beds Dental Clinics With Beds Without Beds Pharmacies
Number of Facilities per 100,000 Population
Total Hospitals Psychiatric Hospitals Infectious Dis. Hospitals Tuberculosis Sanatoria General Hospitals Comprehensive Hospitals re-sum General Practitioners With Beds Without Beds Dental Clinics Pharmacies
Note : Infectious Disease Hospitals were abolished in April 1999.
Source : Hospitals : Ministry of Health, Labour and Welfare, Medical Care Facility Survey, Hospital Report , http://www.mhlw.go.jp/toukei/list/79-1a.html Pharmacies : Ministry of Health, Labour and Welfare, Hygiene Administration Report in Japan , http://www.mhlw.go.jp/toukei/list/36-19a.html
3_参考資料_eng.indd 93
16/03/18 20:55
−94
−
Number of Beds in Medical Care Facilities Japan
Number of Beds Number of Beds
Hospitals Hospitals Psychiatric Care Psychiatric Care Infection Care Infection Care Tuberculosis Care Tuberculosis Care Convalescent Ward Convalescent Ward General Hospitals General Hospitals former Other Facilities General Practitioners former Convalescent Ward re-sum Convalescent Ward re-sum Comprehensive Hospitals re-sum Dental Clinics General Practitioners Total Convalescent Ward re-sum Dental Clinics Total
Number of Beds per 100,000 Population Number of Beds per 100,000 Population
Hospitals Hospitals Psychiatric Care Psychiatric Care Infection Care Infection Care Tuberculosis Care Tuberculosis Care Convalescent Ward Convalescent Ward General Hospitals General Hospitals
General Practitionersre-sum Convalescent Ward re-sum
Comprehensive Hospitals re-sum Dental Clinics General Practitioners Total Convalescent Ward re-sum Dental Clinics Total
Source : Ministry of Health, Labour and Welfare, Medical Care Facility Survey,Hospital Report , http://www.mhlw.go.jp/toukei/list/79-1a.html
3_参考資料_eng.indd 94
16/03/18 20:55
− 95 −
Number of Medical Care Personnel JapanTotal Number
FiscalYear Physicians*1 Dentists*1 Nurses*2 Pharmacists*1
Number per 100,000 PopulationFiscalYear Physicians*1 Dentists*1 Nurses*2 Pharmacists*1
Note : *1. Number of licensed specialists. *2. Number of actual workers including nurses and assistant nurses.
Source : Ministry of Health, Labour and Welfare, Report on Public Health Administration and Services Medical Personnel , http://www.mhlw.go.jp/toukei/list/36-19a.html Ministry of Health, Labour and Welfare, Report on Survey of Physicians, Dentists and Pharmacists, http://www.e-stat.go.jp/SG1/estat/NewList.do?tid=000001030962
3_参考資料_eng.indd 95 16/03/18 20:55
− 96 −
Ajinomoto
Banyu
Torii(Merck)
Torii(Asahi Breweries)
Hokuriku(BASF)
Hokuriku(Abbott)
SSP(NBI)
Shimizu(Ajinomoto)
Ajinomoto Medica(Manufacturing)
Ajinomoto Pharma(Marketing)
Nikken Chemicals(Kowa)
Kayaku(Manufacturing)
Kyowa Hakko(Kirin)
Kyowa Hakko Kirin(Kirin)
POLAPharma
Torii(JT)
MitsubishiTanabe
AbbottJapan
Mitsubishi
AbbottJapan
Chugai(Roche)
UCB
MSD
AbbVie
Nippon Schering
Hisamitsu
BayerYakuhin
BayerYakuhin
Taisho
Taisho Toyama
Toyama Chemical
Astellas
Daiichi Sankyo
Dainippon Sumitomo
ASKA
Kowa
Kowa Pharmaceutical
SSP(NBI)
Torii
Merck
Green Cross
Yoshitomi
Tanabe
Hokuriku
Dainabbott
BASF
Fujirebio
UCB
Nippon Roche
Chugai
Mitsui
Hisamitsu
Tokyo Tanabe
Mitsubishi Chemical(Pharmaceutical Div.)
Nippon Schering
SSP
Nippon Boehringer Ingelheim(NBI)
Taisho
Toyama Chemical
Shimizu
Ajinomoto Pharma(Ajinomoto)
Yamanouchi
Sankyo
Daiichi
Dainippon
Sumitomo
Teikoku Hormone
Fujisawa
Kowa
Grelan
Nikken Chemicals
Asahi Breweries
JT
Welfide
Taisho Toyama
Zepharma
Kayaku
Mitsubishi
Abbott
Kirin Pharma
’83 Acq
’10 Mrg
’98 Mrg
’99 Mrg
’01 Mrg
’03 Intg
’02 Intg
’07 Intg
’00 Pharmaceutical Business Sold
’05 Ethical Drug Sector Sold
’07 Pharmaceutical Business Transferred
’07 Marketing SectorTransferred
’06 Ethical Drug Business Transferred
’05 Business Function Changed
Pharmaceutical Function’05 Business Function Changed
’04 OTC Sector Separated & Merged
’06 Sold
’05 Mrg
’07 Mrg
’05 Mrg
’05 Mrg
’02 Ethical Drug Mkt. Company founded
’88 Acq
’01 Acq
’07 Mrg
’96 Acq
’00 Acq
’01 Acq
’03 Acq
(POLA Chemical)
(Kirin)
POLA Chemical
Kyowa Hakko
Kayaku AntibioticResearch
’83 Capital Participation
’07 Capital Participation
Acq:Acquisition Mrg:Merger Intg:Integration
’84 Company Name Changed
’08 Pharmaceutical Business Separated
Kirin
’08 Mrg
’02 Acq
’98 Acq
’10 Mrg
M&A in Japan
Schering-Plough
Ajinomoto
Ajinomoto Medica
Ajinomoto Pharma
AjinomotoPharma
’13 Sep
Ayumi
SantenSanten
Baxter
’15 Sep
Baxalta
Baxter’15 Sep
Sep:Separation
3_参考資料_eng.indd 96 16/03/18 20:55
− 97 −
M&A in the World
Glaxo(UK)’95 Mrg
Beecham(UK)
SmithKline(US)
Wellcome(UK)Glaxo Wellcome(UK)
SmithKlineBeecham(UK) ’89 Mrg
’00 Mrg GlaxoSmithKline(UK)
Hoechst(Ger)
Rorer(US)
Rhone-Poulenc(Fr)
Marion Merrell Dow(US)
Hoechst (Ger)
Rhone-PoulencRorer(Fr)
Delagrange(Fr)
Delalande(Fr)
Sanofi(Fr)
Synthelabo(Fr)
Aventis (Fr)
’99 Mrg
’04 Acq
’11 Acq
’91 Acq
’91 Acq
Sanofi(Fr)
’90 Mrg
Synthelabo(Fr)
’99 Mrg
Sanofi Synthelabo (Fr)
Roussell(Fr)
Farmitalia(Italy)
Pharmacia(Sweden)
Kabi Vitrum (Sweden)
Carlo Erba(Italy)
Kabi Pharmacia(Sweden)
FarmitaliaCarlo Erba(Italy)
Pharmacia (Sweden)
Upjohn(US)
Monsanto(US)
Wyeth(US)
Searle(US) Monsanto(US)
’78 Mrg
’91 Mrg
’93 Mrg
Pharmacia &Upjohn(US)
’95 Mrg
Pharmacia(US)’00 Mrg
’85 Acq
’03 Acq
’09 Acq
Pfizer(US)
Warner -Lambert(US)’00 Mrg Pfizer(US)
Pfizer(US)
Squibb (US)
Bristol-Myers(US) Bristol -Myers Squibb(US)
’89 Mrg
Schering(Ger)
Bayer(Ger)’06 Acq
Bayer(Ger)
’09 Mrg
’13 Sep
’11 Mrg
Merck(US) Merck(US)
Organon(NL)
Schering Plough(US) Schering Plough(US)’07 Acq
’93 Ethical Drug Sector Separated
I C I(UK)
AstraZeneca(UK)
Zeneca (UK)’99 Mrg
Astra(Sweden)
( I C I )
Roche(Switz)
Roche(Switz)’90 Acq
Genentech(US)
Chugai(JPN)
Syntex(US) Roche(Switz)
Roche(Switz)’94 Acq
’02 Acq
Boehringer Mannheim (Ger)’97 Acq
’98 ReorganizationRoche
DiagnosticsRoche
Diagnostics Company Name changed
Company Name changed
Acq:Acquisition Mrg:Merger Sep:Separation
’06 Acq
’96 MrgSandoz(Switz)
Chiron(US)
Alcon(US)
Novartis(Switz)
Novartis(Switz)
Ciba-Geigy(Switz)
Genzyme(US)
AbbVie(US)
Abbott(US)Abbott(US)
’15 SepBaxalta(US)
Baxter(US)Baxter(US)
3_参考資料_eng.indd 97 16/03/18 20:55
Appendix
扉_eng.indd 7 16/03/18 20:52
AbbVie G.K. 3-5-27 Mita,Minato-ku,Tokyo 108-6302
AJINOMOTO PHARMACEUTICALS CO., LTD. 2-1-1 Irifune, Chuo-ku, Tokyo 104-0042
Alcon Japan LTD.1-23-1 Toranomon,Minato-ku, Tokyo 105-6333
ASAHI KASEI PHARMA CORPORATION1-105 Kanda-Jinbocho,Chiyoda-ku, Tokyo 101-8101
ASKA PHARMACEUTICAL CO., LTD.2-5-1 Shibaura,Minato-ku, Tokyo 108-8532
ASTELLAS PHARMA INC, 2-5-1 Nihonbashi-Honcho,Chuo-ku, Tokyo 103-8411
AstraZeneca K.K. 3-1 Ofukacho, Kita-ku, Osaka 530-0011
AYUMI PHARMACEUTICAL CORP. 4-12-15 Ginza, Chuo-ku, Tokyo 104-0061
BAXALTA, LTD.1-23-1 Toranomon, Minato-ku, Tokyo 105-6320
BAYER YAKUHIN, LTD.2-4-9 Umeda, Kita-ku, Osaka 530-0001
BRISTOL-MYERS K.K.6-5-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1328
Celgene K.K.2-7-2 Marunouchi,Chiyoda-ku, Tokyo 100-7010
CHUGAI PHARMACEUTICAL CO., LTD.2-1-1 Nihonbashi-Muromachi, Chuo-ku, Tokyo 103-8324
DAIICHI SANKYO CO., LTD3-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8426
DAINIPPON SUMITOMO PHARMA CO., LTD.2-6-8 Doshomachi, Chuo-ku, Osaka 541-0045
EISAI CO., LTD.4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088
ELI LILLY JAPAN K.K.7-1-5 Isogamidori, Chuo-ku, Kobe, Hyogo 651-0086
FUJIMOTO PHARMACEUTICAL CORP. 1-3-40 Nishi-Otsuka, Matsubara, Osaka 580-8503
FUSO PHARMACEUTICAL INDUSTRIES, LTD.2-3-11 Morinomiya, Joto-ku, Osaka 536-8523
Genzyme Japan K.K.3-20-2 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1488
GlaxoSmithKline K.K.4-6-15 Sendagaya, Shibuya-ku, Tokyo 151-8566
HISAMITSU PHARMACEUTICAL CO., INC.408 Daikanmachi, Tashiro, Tosu, Saga 841-0017
JANSSEN PHARMACEUTICAL K.K.3-5-2 Nishi-Kanda, Chiyoda-ku, Tokyo 101-0065
JAPAN TOBACCO INC.2-2-1 Toranomon,Minato-ku, Tokyo 105-8422
KAKEN PHARMACEUTICAL CO., LTD.2-28-8 Honkomagome, Bunkyo-ku, Tokyo 113-8650
KISSEI PHARMACEUTICAL CO., LTD.19-48 Yoshino, Matsumoto, Nagano 399-8710
KOWA Company, Ltd.3-4-14 Nihonbashi-Honcho,Chuo-ku, Tokyo 103-8433
KRACIE PHARMA, LTD.3-20-20 Kaigan,Minato-ku, Tokyo 108-8080
KYORIN PHARMACEUTICAL CO., LTD.4-6 Kanda-Surugadai,Chiyoda-ku, Tokyo 101-8311
KYOTO PHARMACEUTICAL INDUSTRIES, LTD.38 Nishinokyo-Tsukinowacho,Nakagyo-ku, Kyoto 604-8444
KYOWA HAKKO KIRIN CO., LTD. 1-6-1 Otemachi,Chiyoda-ku, Tokyo 100-8185
MARUHO CO., LTD.1-5-22 Nakatsu,Kita-ku, Osaka 531-0071
MARUISHI PHARMACEUTICAL CO., LTD.2-4-2 Imazunaka, Tsurumi-ku, Osaka 538-0042
Meiji Seika Pharma CO., LTD. 2-4-16 Kyobashi,Chuo-ku, Tokyo 104-8002
Merck Serono CO., LTD. 1-8-1 Simomeguro,Meguro-ku, Tokyo 153-8926
MINOPHAGEN PHARMACEUTICAL CO. LTD.3-2-11 Nishi-Shinjuku,Shinjuku-ku, Tokyo 160-0023
MITSUBISHI TANABE PHARMA CORPORATION3-2-10 Doshoumachi,Chuo-ku, Osaka 541-8505
MOCHIDA PHARMACEUTICAL CO., LTD.1-7 Yotsuya,Shinjuku-ku, Tokyo 160-8515
Member Companies ofThe Japan Pharmaceutical Manufacturers Association
4_付録_eng.indd 100 16/03/18 20:56
MSD K.K. 1-13-12 Kudan-Kita,Chiyoda-ku, Tokyo 102-8667
Mylan EPD G.K. 3-5-27 Mita,Minato-ku, Tokyo 108-6306
NIHON PHARMACEUTICAL CO., LTD1-9-8 Higashi-Kanda, Chiyoda-ku, Tokyo 101-0031
NIPPON BOEHRINGER INGELHEIM CO., LTD.2-1-1 Osaki,Shinagawa-ku, Tokyo 141-6017
NIPPON CHEMIPHAR CO., LTD.2-2-3 Iwamotocho,Chiyoda-ku, Tokyo 101-0032
NIPPON KAYAKU CO., LTD.2-1-1 Marunouchi,Chiyoda-ku, Tokyo 100-0005
NIPPON SHINYAKU Co., Ltd.14 Nishinosho Monguchicho, Kisshoin,Minami-ku Kyoto 601-8550
NIPPON ZOKI PHARMACEUTICAL CO., LTD.2-1-2 Hiranomachi,Chuo-ku, Osaka 541-0046
NOVARTIS PHARMA K.K.1-23-1 Toranomon,Minato-ku, Tokyo 105-6333
NOVO NORDISK PHARMA LTD.2-1-1 Marunouchi,Chiyoda-ku, Tokyo 100-0005
ONO PHARMACEUTICAL CO., LTD.1-8-2 Kyutaromachi,Chuo-ku, Osaka 541-8564
OTSUKA PHARMACEUTICAL Co., Ltd.2-16-4 Kounan, Minatoku, Tokyo 108-8242
PFIZER JAPAN INC.3-22-7 Yoyogi,Shibuya-ku, Tokyo 151-8589
POLA PHARMA INC.8-9-5 Nishi-Gotanda,Shinagawa-ku, Tokyo 141-0031
Sanofi K.K.3-20-2 Nishi-Shinjuku,Shinjuku-ku, Tokyo 163-1488
SANTEN PHARMACEUTICAL CO., LTD.4-20 Ofukacho,Kita-ku, Osaka 530-8552
SANWA KAGAKU KENKYUSHO CO., LTD.35 Higashi-Sotoboricho,Higashi-ku, Nagoya 461-8631
SEIKAGAKU CORPORATION1-6-1 Marunouchi,Chiyoda-ku, Tokyo 100-0005
SENJU PHARMACEUTICAL CO., LTD. 2-5-8 Hiranomachi,Chuo-ku, Osaka 541-0046
SHIONOGI & CO., LTD.3-1-8 Doshomachi,Chuo-ku, Osaka 541-0045
TAIHO PHARMACEUTICAL CO., LTD.1-27 Kanda-Nishikicho,Chiyoda-ku, Tokyo 101-8444
TAISHO PHARMACEUTICAL CO., LTD.3-24-1 Takata,Toshima-ku, Tokyo 170-8633
TAKEDA PHARMACEUTICAL COMPANY LIMITED4-1-1 Doshomachi,Chuo-ku, Osaka 540-8645
TEIJIN PHARMA LIMITED3-2-1 Kasumigaseki,Chiyoda-ku, Tokyo 100-8585
TEIKOKU SEIYAKU CO., LTD.567 Sanbonmatsu,Higashi-kagawa, Kagawa 769-2695
TERUMO CORPORATION3-20-2 Nishi-Shinjuku,Shinjuku-ku, Tokyo 163-1450
TOA EIYO LTD.3-10-6 Hatchobori,Chuo-ku, Tokyo 104-0032
Toray Industries, Inc.2-1-1 Nihonbashi-Muromachi,Chuo-ku, Tokyo 103-8666
TORII PHARMACEUTICAL CO., LTD.3-4-1 Nihonbashi-Honcho,Chuo-ku, Tokyo 103-8439
TOYAMA CHEMICAL CO., LTD. 3-2-5 Nishi-Shinjuku,Shinjuku-ku, Tokyo 160-0023
TSUMURA & CO., LTD.3-2-5 Nishi-Shinjuku,Shinjuku-ku, Tokyo 160-0023
UCB JAPAN CO., LTD8-17-1 Nishi-Shinjuku,Shinjuku-ku, Tokyo 160-0023
WAKAMOTO PHARMACEUTICAL CO., LTD.2-2-2 Nihonbashi-Honcho,Chuo-ku, Tokyo 103-8330
YAKULT HONSHA CO., LTD.1-1-19 Higashi-Shinbashi,Minato-ku, Tokyo 105-8660
ZERIA PHARMACEUTICAL CO., LTD.10-11 Nihonbashi-Kobunacho,Chuo-ku, Tokyo 103-8351
(as of March, 2016)
4_付録_eng.indd 101 16/03/18 20:56
MEMO
DATA BOOK 2016
4_付録_eng.indd 102 16/03/18 20:56
MEMO
DATA BOOK 2016
4_付録_eng.indd 103 16/03/18 20:56
Exchange Rates
Country Currency CurrencyAbbreviation
Australia AustralianDollar AUD
Canada CanadianDollar CAD
China Yuan CNY
Denmark DanishKrone DKK
Japan Yen JPY
Korea KoreanWon KRW
Sweden SwedishKrone SEK
Switzerland SwissFranc CHF
United Kingdom PoundSterling GBP
United States US Dollar USD
EU Euro EUR
Austria Schilling NLG
Belgium BelgianFranc BEF
France Franc FRF
Germany DeutscheMark DEM
Italy ItalianLira ITL
Netherlands Guilder NLG
Portugal PortugueseEscudo PTE
Spain SpanishPeseta ESP
Notes : Currency unit of EU : The euro has been used in Austria, Belgium, France, Germany, Italy, Netherlands, Portugal and Spain since 1999.
Source : International Financial Statistics Yearbook 2015
4_付録_eng.indd 104
16/03/18 20:56